Akebia Therapeutics Inc (NASDAQ:AKBA) Receives Consensus Rating of “Hold” from Brokerages

Two Sigma Investments LP now owns 19,827 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 1,777 …

Akebia Therapeutics logoShares of Akebia Therapeutics Inc (NASDAQ:AKBA) have received a consensus rating of “Hold” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.40.

AKBA has been the topic of a number of analyst reports. Mizuho reiterated a “buy” rating and issued a $17.00 price target on shares of Akebia Therapeutics in a research note on Tuesday, August 11th. Needham & Company LLC initiated coverage on shares of Akebia Therapeutics in a research note on Tuesday, August 11th. They issued a “buy” rating and a $18.00 price target on the stock. JPMorgan Chase & Co. upped their price target on shares of Akebia Therapeutics from $13.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Morgan Stanley upped their target price on shares of Akebia Therapeutics from $11.00 to $12.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 15th. Finally, HC Wainwright restated a “buy” rating on shares of Akebia Therapeutics in a research note on Wednesday, July 15th.

In other Akebia Therapeutics news, Director Maxine Gowen sold 4,567 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $11.84, for a total transaction of $54,073.28. 2.55% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC increased its position in shares of Akebia Therapeutics by 10.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 8,245 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 800 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Akebia Therapeutics by 13.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,500 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 1,352 shares during the last quarter. Two Sigma Investments LP increased its position in shares of Akebia Therapeutics by 9.8% during the 1st quarter. Two Sigma Investments LP now owns 19,827 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 1,777 shares during the last quarter. Private Advisor Group LLC purchased a new stake in shares of Akebia Therapeutics during the 2nd quarter valued at about $25,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of Akebia Therapeutics during the 2nd quarter valued at about $28,000. 76.75% of the stock is owned by hedge funds and other institutional investors.

(Ad)

There’s a reason so few investors are ever able to beat the market: they’ve been lied to. They have no idea what really drives stock prices. When you discover exactly why stocks rise or fall, it’s easy to avoid losers and find more, bigger winners.

Shares of Akebia Therapeutics stock opened at $9.95 on Wednesday. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -3.32 and a beta of 1.20. The firm’s 50-day moving average is $11.12 and its 200 day moving average is $10.06. Akebia Therapeutics has a 1 year low of $2.99 and a 1 year high of $13.71. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.29 and a quick ratio of 1.76.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.02. Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 55.64%. On average, equities analysts expect that Akebia Therapeutics will post -1.53 EPS for the current fiscal year.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.

Featured Article: Call Option Volume

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Top Fifteen Highest-Rated Dividend Companies

MarketBeat tracks approximately 175,000 ratings each year and tracks more than 15,000 securities around the globe that pay dividends each month or quarter.

This slide show lists the 15 dividend-paying companies (having yields above 25%) that also have the highest average analyst recommendations from Wall Street’s equities research analysts over the last 12 months.

View the “Top Fifteen Highest-Rated Dividend Companies”.